MacroGenics (MGNX)
Develops engineered antibody therapies for cancer through internal programs and collaborations.
$3.91
vs last close−0.22 (−5.22%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 49 days
EPS estimate
−$0.10
Revenue estimate
$39.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.25−$0.65−$0.57$0.27−$0.22−$0.58$0.31Pending
Estimate−$0.23−$0.61−$0.59−$0.48−$0.42−$0.57−$0.08−$0.10
Surprise−8.7%−6.6%+3.4%+156.3%+47.6%−1.8%+498.2%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$17.7M$13.2M$22.2M$72.8M$41.2M$20.8M$32.8MPending
Estimate$34.2M$11.8M$24.4M$27.8M$34.6M$15.2M$59.1M$39.2M
Surprise−48.1%+12.1%−8.9%+161.9%+19.2%+36.3%−44.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.34 | — | — |
| Sep 2027 | −$0.51 | — | — |
| Jun 2027 | −$0.43 | — | — |
| Mar 2027 | −$0.38 | — | — |
| Dec 2026 | −$0.51 | — | — |
| Nov 2026 | −$0.10 | — | — |
| Aug 2026 | −$0.08 | $0.31 | +498.2% |
| May 2026 | −$0.57 | −$0.58 | −1.8% |
| Mar 2026 | −$0.42 | −$0.22 | +47.6% |
| Nov 2025 | −$0.48 | $0.27 | +156.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.34 | — | — | $1.5M | — | — | — |
| Sep 2027 | −$0.51 | — | — | $8.3M | — | — | — |
| Jun 2027 | −$0.43 | — | — | $18.3M | — | — | — |
| Mar 2027 | −$0.38 | — | — | $1.5M | — | — | — |
| Dec 2026 | −$0.51 | — | — | $19.9M | — | — | — |
| Nov 11, 2026 | −$0.10 | — | — | $39.2M | — | — | — |
| Aug 13, 2026 | −$0.08 | $0.31 | +498.2% | $59.1M | $32.8M | −44.5% | +3.4% |
| May 13, 2026 | −$0.57 | −$0.58 | −1.8% | $15.2M | $20.8M | +36.3% | −2.0% |
| Mar 9, 2026 | −$0.42 | −$0.22 | +47.6% | $34.6M | $41.2M | +19.2% | +45.3% |
| Nov 12, 2025 | −$0.48 | $0.27 | +156.3% | $27.8M | $72.8M | +161.9% | −3.3% |
| Aug 14, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 5, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 6, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 15, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Jul 29, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Jul 30, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 25, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 1, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 7, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 2, 2017 | |||||||
| May 3, 2017 | |||||||
| Feb 28, 2017 | |||||||
| Nov 2, 2016 | |||||||
| Aug 3, 2016 | |||||||
| May 4, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 4, 2015 | |||||||
| Aug 5, 2015 |